MedTrace Logo

A Study of Ustekinumab Treatment in Children With Crohn's Disease

NCT05242458 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 545

Last updated 2025-05-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness of ustekinumab in achieving clinical remission in pediatric participants (greater than or equal to \[\>=\] 2 to less than \[\<\] 18 years and weight \>= 40 kilograms \[kg\] at baseline).

Conditions

Interventions

DRUG

Ustekinumab

No interventions will be administered as a part of this study. Participants will receive ustekinumab as per their routine clinical practice.

Sponsors & Collaborators

  • ImproveCareNow (ICN)

    collaborator OTHER

  • Children's Hospital Medical Center, Cincinnati

    collaborator OTHER

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Eligibility

Min Age
2 Years
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-21
Primary Completion
2023-05-22
Completion
2023-05-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05242458 on ClinicalTrials.gov